Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 8/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.41 |
| ▸ | EGFR | P00533 | 13/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3480972 | 0.90 | CDK2 (0.41) | CDK2CCNE1EGFRPOLBMAPT | |
| SCHEMBL3480694 | 0.83 | PSEN1 (0.42) | CDK2CCNE1EGFRPOLBMAPT | |
| SCHEMBL8144017 | 0.80 | HSP90AA1 (0.49) | — | |
| SCHEMBL8141002 | 0.79 | PSEN1 (0.41) | CDK2CCNE1POLBMAPT | |
| SCHEMBL3480701 | 0.78 | CDK2 (0.43) | CDK2CCNE1EGFRPOLBMAPT | |
| SCHEMBL3480971 | 0.77 | MAP4K1 (0.40) | CDK2CCNE1EGFR | |
| SCHEMBL3480967 | 0.76 | CCR4 (0.43) | CDK2CCNE1EGFR | |
| SCHEMBL8141252 | 0.76 | CCNE1 (0.47) | CDK2CCNE1MAPT | |
| SCHEMBL3480697 | 0.74 | CCNE1 (0.41) | CDK2CCNE1EGFRPOLBMAPT | |
| SCHEMBL3480857 | 0.74 | IGLV6-57 (0.38) | CDK2CCNE1EGFRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252803-B2 | Piperidine derivatives | MERCK SHARP & DOHME CORP. (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252803-B2 | Piperidine derivatives | MERCK SHARP & DOHME CORP. (US) | 2012-08-28 | — | — | US | disclosed |
| US-8252803-B2 | Piperidine derivatives | MERCK SHARP & DOHME CORP. (US) | 2012-08-28 | — | — | US | disclosed |
| US-20100041680-A1 | PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME CORP. | 2010-02-18 | — | — | US | disclosed |
| US-20100041680-A1 | PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME CORP. | 2010-02-18 | — | — | US | disclosed |
| US-20100041680-A1 | PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME CORP. | 2010-02-18 | — | — | US | disclosed |
| WO-2008100412-A1 | PIPERIDINE DERIVATIVES | MERCK & CO., INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041680-A1 | PIPERIDINE DERIVATIVES | PSEN1, PSEN2, APBA1 | CDK2 1996/4885CCNE1 3134/4885EGFR 4050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.